Abstract
CDC25 dual specificity phosphatases activate the cyclin-dependent kinase complexes, allowing timely ordered progression through out the different phases of the eukaryotic cell cycle. In humans, there are three genes coding for the CDC25A, B and C proteins with both different and redundant specificities and regulations. The CDC25A member of this family acts during the G1 phase and at the G1/S transition by activating the CDK2/cyclin E and CDK2/cyclin A complexes, a function apparently not shared by the other members. In consequence, CDC25A is submitted to extra-cellular signals-dependent regulations involving in particular mitogenic signal transducers, and leading to modifications of its stability, its localization or its activity. In addition, CDC25A is up-regulated in various cancers, and the molecular mechanisms leading to this up-regulation are far from being understood. In this review, we will synthesize the current knowledge about CDC25A molecular regulations, and try to integrate these data in the cell proliferation and apoptotic functions described for the protein.
Keywords: CDC25A phosphatase, cell cycle, proliferation, apoptosis, G1/S transition, oncogenesis
Anti-Cancer Agents in Medicinal Chemistry
Title: CDC25A: A Rebel Within the CDC25 Phosphatases Family?
Volume: 8 Issue: 8
Author(s): Anne Fernandez-Vidal, Anne Mazars and Stephane Manenti
Affiliation:
Keywords: CDC25A phosphatase, cell cycle, proliferation, apoptosis, G1/S transition, oncogenesis
Abstract: CDC25 dual specificity phosphatases activate the cyclin-dependent kinase complexes, allowing timely ordered progression through out the different phases of the eukaryotic cell cycle. In humans, there are three genes coding for the CDC25A, B and C proteins with both different and redundant specificities and regulations. The CDC25A member of this family acts during the G1 phase and at the G1/S transition by activating the CDK2/cyclin E and CDK2/cyclin A complexes, a function apparently not shared by the other members. In consequence, CDC25A is submitted to extra-cellular signals-dependent regulations involving in particular mitogenic signal transducers, and leading to modifications of its stability, its localization or its activity. In addition, CDC25A is up-regulated in various cancers, and the molecular mechanisms leading to this up-regulation are far from being understood. In this review, we will synthesize the current knowledge about CDC25A molecular regulations, and try to integrate these data in the cell proliferation and apoptotic functions described for the protein.
Export Options
About this article
Cite this article as:
Fernandez-Vidal Anne, Mazars Anne and Manenti Stephane, CDC25A: A Rebel Within the CDC25 Phosphatases Family?, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (8) . https://dx.doi.org/10.2174/187152008786847684
DOI https://dx.doi.org/10.2174/187152008786847684 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Function and Regulation of BMP6 in Various Kinds of Stem Cells
Current Pharmaceutical Design Characteristics of Brain Tumor Stem Cells and the Rationale for Applying Tyrosine Kinase Inhibitors as Potential Targeting Agents
Recent Patents on Regenerative Medicine The Recent Medicinal Chemistry Development of Jak2 Tyrosine Kinase Small Molecule Inhibitors
Current Medicinal Chemistry Repurposing Pharmaceuticals as Neuroprotective Agents for Cerebral Malaria
Current Clinical Pharmacology Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences Functional Role of Glycosphingolipids in Cancer
Current Medicinal Chemistry Editorial (Thematic Issue: Chemical and Biological Technology for In Vivo and Molecular Imaging)
Current Topics in Medicinal Chemistry Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets Contribution of Inflammation to Fat Redistribution and Metabolic Disturbances in HIV-1 Infected Patients
Current Pharmaceutical Design Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Current Pharmaceutical Design Curcumin Nanomedicine: A Road to Cancer Therapeutics
Current Pharmaceutical Design Multiple Roles of Annexin A2 in Post-Transcriptional Regulation of Gene Expressio
Current Protein & Peptide Science Antineovascular Agents in the Treatment of Eye Diseases
Current Pharmaceutical Design New Biomarkers for Colon Cancer Diagnosis: A Review of Recent Patents
Recent Patents on Biomarkers Polyethyleneimine-Based Nanocarriers for Gene Delivery
Current Pharmaceutical Design Poly(ADP-Ribosylation): Beneficial Effects of Its Inhibition
Current Enzyme Inhibition On the Future Development of Optimally-Sized Lipid-Insoluble Systemic Therapies for CNS Solid Tumors and Other Neuropathologies
Recent Patents on CNS Drug Discovery (Discontinued) Mechanosensitive Ion Channels as Drug Targets
Current Drug Targets - CNS & Neurological Disorders Between Bench and Bed Side: PI3K Inhibitors
Current Molecular Pharmacology